Verona Pharma PLC | |
Stock Exchange | London Stock Exchange |
EPS |
GBP0.1 |
Market Cap |
GBP61.62 M |
Shares Outstanding |
99.01 M |
Public Float |
71.55 M |
Address |
3 More London Riverside London Greater London SE1 2RE United Kingdom |
Employees | - |
Website | http://veronapharma.com |
Updated | 07/08/2019 |
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. Verona Pharma's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. |